Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach-Reference-Cited by-同舟云学术

Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach

Published:2021-01 Issue:2 Volume:35 Page:329-337
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Tsakok T.¹²^ORCID,Rispens T.³,Spuls P.⁴,Nast A.⁵^ORCID,Smith C.¹²^ORCID,Reich K.⁶^ORCID

Affiliation:

1. St John’s Institute of Dermatology Guy’s and St Thomas’ NHS Foundation Trust London UK

2. Department of Medical and Molecular Genetics School of Basic and Medical Biosciences Faculty of Life Sciences and Medicine King's College London London UK

3. Department of Immunopathology Sanquin Research and Landsteiner Laboratory Academic Medical Centre Amsterdam Netherlands

4. Department of Dermatology Academic Medical Center University of Amsterdam Amsterdam The Netherlands

5. Department of Dermatology, Venereology und Allergy Division of Evidence‐based Medicine (dEBM) Charité ‐ Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin Humboldt‐Universität zu Berlin Berlin Institute of Health Berlin Germany

6. Translational Research in Inflammatory Skin Diseases Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg‐Eppendorf Skinflammation Center Hamburg Germany

Funder

Medical Research Council

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.16980

Reference63 articles.

1. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

2. NastASC SpulsPI.EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations. JEADV. accepted for publication.

3. NastASC SpulsPI.EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations JEADV. accepted for publication.

5. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Successful Switch From Ustekinumab to an Extended Dosing Interval of Guselkumab Without Induction in a Patient With Psoriasis Vulgaris;Cureus;2024-06-03

2. Functional Genomics and Insights into the Pathogenesis and Treatment of Psoriasis;Biomolecules;2024-05-03

3. Principles of Systemic Therapy;Rook's Textbook of Dermatology;2024-02-20

4. Immunogenicity and pharmacokinetics of guselkumab among patients with moderate‐to‐severe psoriasis in VOYAGE‐1 and VOYAGE‐2;Journal of the European Academy of Dermatology and Venereology;2023-07-28

5. Development of antidrug antibodies against adalimumab maps to variation within the HLA-DR peptide-binding groove;JCI Insight;2023-02-22